Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 2/20 | 0.79 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.61 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.61 |
| ▸ | TRPM2 | O94759 | 1/20 | 0.61 |
| ▸ | LDHA | P00338 | 1/20 | 0.61 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.61 |
| ▸ | FBP1 | P09467 | 1/20 | 0.61 |
| ▸ | SRC | P12931 | 1/20 | 0.61 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.61 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.61 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.61 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.61 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.61 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.61 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.61 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.61 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.61 |
| ▸ | P2RY11 | Q96G91 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL888085 | 1.00 | ADORA1 (0.79) | ADORA1DNPH1PRKAB2TRPM2LDHA | |
| SCHEMBL2217172 | 1.00 | ADORA1 (0.79) | ADORA1DNPH1PRKAB2TRPM2LDHA | |
| SCHEMBL17438017 | 0.96 | ADORA1 (0.79) | ADORA1DNPH1PRKAB2TRPM2LDHA | |
| SCHEMBL8325770 | 0.94 | ADORA1 (0.85) | ADORA1DNPH1PRKAB2TRPM2LDHA | |
| SCHEMBL30670292 | 0.92 | ADORA1 (0.76) | ADORA1DNPH1PRKAB2TRPM2LDHA | |
| SCHEMBL4296364 | 0.92 | ADORA1 (0.69) | ADORA1DNPH1PRKAB2TRPM2LDHA | |
| SCHEMBL15329077 | 0.92 | ADORA1 (0.75) | ADORA1DNPH1PRKAB2TRPM2LDHA | |
| SCHEMBL30582997 | 0.92 | ADORA1 (0.75) | ADORA1DNPH1PRKAB2TRPM2LDHA | |
| SCHEMBL21314872 | 0.90 | ADORA1 (0.64) | ADORA1SMN1; SMN2 | |
| SCHEMBL29384896 | 0.90 | ADORA1 (0.64) | ADORA1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 197 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4662311-A2 | REVERSIR MOLECULES AND METHODS OF USE THEREOF | Alnylam Pharmaceuticals, Inc. (US) | 2025-12-17 | — | — | EP | claimed |
| EP-4594484-A2 | POLYNUCLEIC ACID MOLECULES FOR INHIBITING EXPRESSION OF FXI, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | Sirius Therapeutics, Inc. (US) | 2025-08-06 | — | — | EP | claimed |
| WO-2025128614-A1 | METHODS AND COMPOSITIONS FOR TREATING AN ANGIOTENSINOGEN- (AGT-) ASSOCIATED DISORDER | ALNYLAM PHARMACEUTICALS, INC. (US) | 2025-06-19 | — | — | WO | claimed |
| EP-4569114-A2 | POLYNUCLEIC ACID MOLECULES TARGETING APOC3 AND USES THEREOF | Sirius Therapeutics, Inc. (US) | 2025-06-18 | — | — | EP | claimed |
| EP-4568682-A2 | POLYNUCLEIC ACID MOLECULES FOR INHIBITING EXPRESSION OF LP(A), PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | Sirius Therapeutics, Inc. (US) | 2025-06-18 | — | — | EP | claimed |
| CN-120077134-A | APOC 3-targeted polynucleic acid molecule and application thereof | 靖因药业有限公司 | 2025-05-30 | — | — | CN | claimed |
| CN-120077136-A | SiRNA and drug for inhibiting Amyloid Precursor Protein (APP) gene expression and application thereof | 广州必贝特医药股份有限公司 | 2025-05-30 | — | — | CN | claimed |
| CN-120076811-A | Polynucleic acid molecules, pharmaceutical compositions and uses thereof for inhibiting the expression of Lp (a) | 靖因药业有限公司 | 2025-05-30 | — | — | CN | claimed |
| EP-4547843-A2 | INHIBITORY NUCLEIC ACIDS FOR ITFG1 | Lerna Biopharma Pte. Ltd. (SG) | 2025-05-07 | — | — | EP | claimed |
| CN-119907856-A | 17 Beta-hydroxysteroid dehydrogenase 13 (HSD 17B 13) iRNA compositions and methods of use thereof | 阿尔尼拉姆医药品有限公司 | 2025-04-29 | — | — | CN | claimed |
| EP-4114949-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF TRANSTHYRETIN (TTR) | Alnylam Pharmaceuticals, Inc. (US) | 2023-01-11 | — | — | EP | claimed |
| WO-2023278576-A1 | METHODS AND COMPOSITIONS FOR TREATING AN ANGIOTENSINOGEN- (AGT-) ASSOCIATED DISORDER | ALNYLAM PHARMACEUTICALS, INC. (US) | 2023-01-05 | — | — | WO | claimed |
| EP-4107270-A1 | METHOD OF STIMULATING PROLIFERATION OF A CELL | Agency for Science, Technology and Research (SG) | 2022-12-28 | — | — | EP | claimed |
| CN-115461460-A | Compositions and methods for inhibiting expression of transthyretin (TTR) | 阿尔尼拉姆医药品有限公司 | 2022-12-09 | — | — | CN | claimed |
| EP-4058577-A1 | METHODS AND COMPOSITIONS FOR TREATING AN ANGIOTENSINOGEN- (AGT-) ASSOCIATED DISORDER | Alnylam Pharmaceuticals, Inc. (US) | 2022-09-21 | — | — | EP | claimed |
| CN-114981431-A | Methods and compositions for treating Angiotensinogen (AGT) -related disorders | 阿尔尼拉姆医药品有限公司 | 2022-08-30 | — | — | CN | claimed |
| EP-3969588-A1 | COMPOSITIONS AND METHODS FOR TREATING HEPATITIS B VIRUS (HBV) INFECTION | VIR Biotechnology, Inc. (US) | 2022-03-23 | — | — | EP | claimed |
| CN-108368507-B | iRNA compositions of programmed cell death 1 ligand 1(PD-L1) and methods of use thereof | 阿尔尼拉姆医药品有限公司 | 2022-03-22 | — | — | CN | claimed |
| CN-114126628-A | Compositions and methods for treating Hepatitis B Virus (HBV) infection | 维尔生物科技有限公司 | 2022-03-01 | — | — | CN | claimed |
| WO-2022025827-A1 | METHOD OF STIMULATING PROLIFERATION OF A CELL | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2022-02-03 | — | — | WO | claimed |